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Agammaglobulinaemia despite terminal B-cell
differentiation in a patient with a novel LRBA mutation
Nashat Al Sukaiti1, Khwater AbdelRahman2, Jalila AlShekaili3, Sumaya Al Oraimi4, Aisha Al Sinani5,
Nasser Al Rahbi6, Vicky Cho7, Matt Field7 and Matthew C Cook7,8
Mutations in lipopolysaccharide-responsive vesicle trafficking, beach and anchor-containing protein (LRBA) cause immune
deficiency and inflammation. Here, we are reporting a novel homozygous mutation in LRBA allele in 7-year-old Omani boy, born
to consanguineous parents. He presented with type 1 diabetes, autoimmune haematological cytopenia, recurrent chest infections
and lymphocytic interstitial lung disease. The patient was treated with CTLA4-Ig (abatacept) with good outcome every 2 weeks
for a period of 3 months. He developed complete IgG deficiency, but remarkably, histological examination revealed germinal
centres and plasma cells in lymphoid and inflamed lung tissue. Further charatecterisation showed these cells to express IgM but
not IgG. This ex vivo analysis suggests that LRBA mutation confers a defect in class switching despite plasma cell formation.
Clinical & Translational Immunology (2017) 6, e144; doi:10.1038/cti.2017.20; published online 26 May 2017
Lipopolysaccharide-responsive vesicle trafficking, beach and anchor-
containing protein (LRBA) is one of nine known mammalian BEACH
domain-containing proteins (BDCP). BDCPs serve as scaffolds for
multi-molecular complexes that are important for guiding and
regulating vesicular trafficking.1,2 So far, mutations in the genes
encoding four BDCP family members have been reported to cause
Mendelian disease (LYST, NBEAL2, WDR81 and LRBA). Homozygous
or biallelic mutations in LRBA have been described in patients with
early onset and often severe autoimmunity and antibody deficiency.3
LRBA regulates intracellular trafficking of CTLA, a negative regulator
of T-cell immunity.4 Reported cases arising from LRBA mutations
exhibit considerable phenotypic variation, even in individuals
carrying the same mutation, and histopathological abnormalities
include granulomas in skin, lungs and central nervous system, and
lymphocytic infiltrates of lung and lamina propria in the gut.5–9
Recurrent infections occur in the majority, and immune-mediated
thrombocytopenia, enteropathy and hypogammaglobulinaemia, each
reported in ~ 50% of cases.
Reported immunologic findings are variable, and include decreased
B cells, and deficiency of CD4+ T-regulatory (Treg) cells.10 Here,
we report a novel homozygous nonsense mutation of LRBA resulting
in autoimmunity and immune deficiency. We report the presence
of normal germinal centre formation and, more remarkably,
plasma cells in lymph node and inflamed parenchymal tissue despite
agammaglobulinaemia.
CASE REPORT
A 7-year-old Omani boy born to a consanguineous parent presented at
the age of 9 months with type 1 diabetes, and was started on insulin
replacement therapy. At the same time, he was found to have
hepatosplenomegaly. He had two younger healthy male siblings. There
was a family history of major histocompatibility complex class II
deficiency due to a CIITA missense mutation (M1071T); neither
proband nor his parents carried this mutation (Figure 1). At the age of
2 years, he developed repeated episodes of immune-mediated throm-
bocytopenia, which were managed successfully with high-dose intra-
venous immunoglobulin and prednisolone (Table 1). He remained in
remission from immune-mediated thrombocytopenia for 2 months
then developed Evan’s syndrome, (direct Coomb’s test-positive auto-
immune haemolytic anaemia and immune-mediated thrombocytope-
nia), which failed to respond to either intravenous immunoglobulin or
pulse methylprednisolone. At the age of 3 years, he was treated with
four doses of rituximab, which induced a sustained remission. At the
age of 4 years, a year after the last dose of rituximab treatment,
however, he developed bacterial infections, which became recurrent.
These included tonsillitis, otitis media, three bouts of pneumonia and
one episode of acute salmonella gastroenteritis. At the age of 5 years,
he was admitted with tachypnea and shortness of breath.
Chest X-ray at the age of 5 years showed interstitial lung infiltrates
and hilar lymphadenopathy (Figure 2a). Bronchoalveolar lavage was
positive for cytomegalovirus by PCR, however, there were no inclusion
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bodies seen by histopathology. At that time, cytomegalovirus DNA was
detected at only 75 copies per ml in serum by PCR, however, this
increased to 2434 copies per ml 1 month later. He was treated with
intravenous ganciclovir 5 mg kg− 1 twice a day followed by oral
valganciclovir 15 mg kg− 1 twice a day for a total of 6 weeks.
Cytomegalovirus DNA was undetectable after treatment. Aspergillus
niger was isolated from bronchoalveolar lavage. Blood cultures were
negative. He received 6 weeks treatment with voriconazole after which
repeated bronchoalveolar lavage was negative for aspergillus. Despite
administration of appropriate antimicrobial therapy, radiological
changes persisted. High-resolution chest computed tomography scan
was consistent with lymphocytic interstitial pneumonitis (Figure 2b).
Investigations at age 2 years (before rituximab treatment) revealed
marked polyclonal hypergammaglobulinaemia (IgG 432.2 g l− 1),
Figure 1 Family pedigree of the proband (black and arrow) and the relatives with MHC class II deficiency (green).
Table 1 Summary of immunological laboratory findings
Age in years 2 years 5 years 6 years 7 years
Test
IgG (3.5–12 g l−1) 432.2 o1.0 4.5 6.9
IgA (0.15–1.6 g l−1) 1.7 o0.05 o0.05 o0.05
IgM (0.4–2 g l−1) 0.7 o0.05 1.65 4.99
IgE (0–90 IU ml−1) o15
Hep B antibody NR
Measles, mumps and rubella antibodies NR NR
CD3 (1.0–2.0×109) ND 5.210 3.260 0.730
CD4 (0.5–1.3×109) ND 1.230 0.860 0.820
CD8 (0.3–1.0×109) ND 3.510 2.030 1.730
CD19 (0.2–0.5×109 ) ND 0.410 0.300 0.190
CD20 (6–23%) ND o1 2.7 3.6
CD16/56 (cells per μl) ND 0.840 0.450 0.090
%CD3+CD4+ 33.4% (27.7–46.3)
%CD4+CD45RA+CCR7+ (naive CD4 cells) 5.2% (29.2–66.5)
%CD4+CD45RA−CCR7+ (central memory CD4T cells) 63.3% (11.6–24.7)
%CD4+CD45RA−CCR7− (effector memory CD4T cells) 20.7% (7.1–21.4)
%CD4+CD45RA+CCR7− (terminally differentiated CD4T cells) 10.7% (6.9–34.4)
%CD3+CD8+ 51.5% (15.7–33.8)
%CD8+CD45RA+CCR7+ (naive CD8T cells) 4.9% (8.6–50.1)
%CD8+CD45RA−CCR7+ (central memory CD8T cells) 4.5% (1–4.6)
%CD8+CD45RA−CCR7− (effector memory CD8T cells) 44.4% (16–47.2)
%CD8+CD45RA+CCR7− 46.1% (19.5–52.5)
%CD3+CD4+CD62L+CD31+ (recent thymic emigrant) 9% (19.4–60.9)
%CD19+ 7% (9.7–23.7)
% CD19+IgD+CD27− (naive B cell) 80.1% (47.3–77.0)
%CD19+CD27+IgD+ memory B cell 15.4% (5.2–20.4)
%CD19+CD27+IgD− memory B cell 0.4% (10.9–30.4)
%CD19+CD27−IgD− memory B cell 4.0% (2.3–11.0)
%CD19+CD24hiCD38hi transitional B cell 20.2% (4.6–8.3)
%CD19+CD21loCD38lo 38% (2.3–10.0)
%CD19+CD24loCD38hi plasmablast 0.8% (0.6–5.3)
Abbreviations: ND, not done; NR, not reactive.
Reference ranges.17,18
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with normal IgA, IgM and IgE (Table 1). At age 5 years (2 years after
rituximab treatment), he was noted to be agammaglobulinemic.
Lymphocyte subset analysis performed at age 5 years showed absence
of CD20+ B cells, which started to recover by the age of 6 years old.
Flow cytometric assessment of peripheral B-cell subsets at the age of
7 years revealed reduction in memory B cells and increased CD21+
B cells compared to normal controls of similar age group (Figure 3a).
Transitional B cells were evident (CD24hi CD38hi). Flow cytometric
analysis of different T-cell subsets revealed marked reduction of naive
cells in both CD4+ and CD8+ T-cell compartments, an inverted ratio
of CD4:CD8T cells (Table 2). Moreover, there was an expansion of
circulating follicular helper T cells (cTfH) marked by high number
of CD4+ PD-1+CD45RA− compared to normal controls (n= 10)
(Figures 3b and c).
Biopsies from lung obtained when the patient was 5 years old
revealed type two pneumocyte hyperplasia. Alveolar septa were
markedly expanded, with nodular lymphoid aggregates containing
germinal centres identified by H&E. A cervical lymph node biopsy
obtained at the same time revealed follicular hyperplasia with
histiocytic microgranulomas and aggregates of monocytoid B cells.
The lymphoid follicles showed prominent germinal centres confirmed
by immunohistochemistry (CD10+). Abundant Ig kappa and Ig
lambda positive plasma cells were identified, consistent with a
polyclonal plasma cell response, although no IgG+ cells were present
(Figure 3d). Bone marrow examination was hypercellular with plasma
cells present and no other specific changes.
Whole-exome sequencing was performed and analysed for known
monogenic causes of primary immune deficiency or autoimmunity.
Figure 2 Radiological findings. Chest X-ray and high-resolution computed tomography scan showing interstitial lung infiltrates and hilar lymphadenopathy.
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Figure 3 T- and B-cell phenotypes and tissue plasma cell infiltrate. (a) Flow cytometry analysis of B-cell subsets; naive (CD19+CD27−) and memory
(CD19+CD27+) B cells, CD21low CD19+ B cells in peripheral blood mononuclear cells (PBMCs) from patient and a healthy control. (b) CD4+ T-cell subsets
(naive, CCR7+CD45RA+; TCM, CCR7+CD45RA−; TEM, CCR7−CD45RA−; TEMRA, CCR7−CD45RA+) and cTFH (CD45RA−PD-1+) from patient and a healthy
control. (c) Summary for the cTFH obtained for the proband and normal controls (n=10). (d) Biopsies from lymph node with follicular hyperplasia showing
reactive secondary follicles (H&E, 50× ). Lymph node immunohistochemistry showing established germinal centres, CD10 immunoperoxidase (50× ), and
kappa and lambda light chain and immunoglobulin isotype expression.
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We identified a novel homozygous nonsense mutation in LRBA (Chr4:
R1271X; g.163829C4T; c.4285C4T). The mutation was confirmed
by Sanger sequencing, and both parents were confirmed as hetero-
zygous for the same mutation (Figures 4b and c). LRBAR1271X has not
been reported in 1000Genomes, dbSNP, ClinVar, ExAC or HGMD,
and has not been detected in 4200 in-house exome sequences from
unrelated individuals. The stop is predicted to result in loss of protein
due to nonsense mediated decay of LRBA transcripts. After obtaining
this molecular diagnosis, the patient was treated with abatacept
(10 mg kg− 1) every 2 weeks for 3 months at the time of writing this
article. He showed remarkable clinical improvement in term of his
shortness of breath, and his weight gain as well as clearance of X-ray
(Figure 4a).
DISCUSSION
We have reported a novel allele of LRBA presenting with type 1
diabetes, autoimmune cytopenias and severe lymphocytic
pneumonitis. At initial assessment, the patient had polyclonal
hypergammaglobulinaemia, but he subsequently became agammaglo-
bulinaemic. Although he had been treated with rituximab,
agammaglobulinaemia was noted 412 months after his treatment.
He was commenced on intravenous immunoglobulin precluding
further assessment of endogenous IgG production, but he remained
IgA deficient for at least 4 years after rituximab. It is noteworthy that
despite agammaglobulinaemia, histological examination of lung and
lymph node revealed abundant germinal centres with plasma cells
being present. While plasma cells appeared polyclonal by Ig kappa and
Ig lambda staining, they were negative for IgG.
BDCPs are thought to assemble macromolecular complexes that
regulate vesicular trafficking and function.1 The ultra structural
signatures of LRBA mutation include disordered autophagy, resulting
in increased apoptosis3 and altered trafficking of CTLA4.4 The
significance of the latter observation is borne out by the efficacy
of abatacept therapy, as illustrated by our case. Nevertheless,
manifestations of LRBA deficiency vary substantially from patient to
patient. In Chediak–Higashi syndrome, which results from mutations
in the BDCP family member LYST, phenotypic variation has been
related to genotype, with milder phenotypes in patients with missense
mutations.11 While there is genetic heterogeneity among the LRBA
mutant cases reported to date (~50), all reported cases arise from
nonsense mutations, indels or large deletions.
Clinical resemblance to autoimmune lymphoproliferative
syndrome, deficiency of Tregs and response to abatacept indicate that
T-cell dysregulation is an important cause of autoimmunity and
inflammation in LRBA deficiency. Furthermore, clinical improvement
has been noted in at least two cases treated with hematopoietic stem
Table 2 Case histology chronology
Age Complication Hb (g l−1) N (×109 l−1) Plt (x109 l−1) IgG (g l−1) IgA (g l−1) IgM (g l−1) CD19 (×109 l−1) Treatment
0.9 T1D 13.3 1.8 250 Insulin
2.3 ITP 12.9 2.1 13 430 1.7 0.7 IVIg
2.8 AIHA, ITP 7.0 1.6 1 IVIg, prednisolone
3.0 ITP 12.5 5.5 3 IVIg, prednisolone
3.2 ITP 13.6 3.9 21 RTX
4.2 Pneumonia, OM, gastroenteritis 12.9 3.2 255 o1 0.05 0.05 0 Antibiotics
5.2 Pneumonia (CMV), LIP, HS 11.1 2.1 148 4.5 0.05 1.65 0.3 GCV, VCZ, IVIg, MP
6.5 Pneumonia (Haemophilus influenzae), LIP, HS 11.8 2.4 171 6.9 0.05 4.99 3.6 IVIg, MP, MMF
7.9 LIP, HS 12.3 1.7 268 ABCT, IVIg
Abbreviations: ABCT, abatacept; AIHA, autoimmune haemolytic anaemia; CMV, cytomegalovirus; GCV, ganciclovir; HS, hepatosplenomegaly; ITP, immune-mediated thrombocytopenia; IvIg, intravenous
immunoglobulin; LIP, lymphocytic interstitial pneumonitis; MMF, mycophenolate mofetil; MP, methylprednisolone; OM, otitis media; RTX, rituximab; T1D, type 1 diabetes; VCZ, voriconazole.
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Figure 4 Diagnosis and therapy. (a) Comparison of chest X-rays taken before and 3 months after abatacept therapy. (b) DNA chromatograms of LRBA
showing heterozygous mutations in the parents (upper panels) and homozygous mutation in the proband. (c) Location of nonsense mutation in exon diagram
of LRBA.
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cell transplantation, although it is interesting to note that recurrent or
persistent thrombocytopenia and progressive vitiligo was reported
even in the face of documented microchimerism.12,13
Hypogammaglobulinaemia is common but not universal with
LRBA deficiency. Indeed, as illustrated in our case, an increase in
immunoglobulin can be observed early in the natural history. The
pathophysiology of immune deficiency related to LRBA mutation
remains incompletely understood. Remarkably, we have shown
agammaglobulinaemia in the face of germinal centre formation, and
present plasma cells. This suggests that within the B-cell compartment,
immunoglobulin deficiency arises as a result of plasma cell dysfunction
not deficiency. Future studies will be necessary to determine the nature
of this functional defect.
METHODS
Approved hospital consent was taken for the genetic analysis for the patient and
his parents.
Cellular T-and B-cell phenotype (flow cytometry): the following antibodies
were used for flow cytometry staining from Beckman Coulter (Brea, CA, USA):
anti-CD45-Krome Orange (clone J33), anti-CD19-Red-X (ECD) (clone J3-
119), and anti-CD21-PE (clone BL13), anti-CD27-PC7 (clone 1A4CD27), and
anti-CD38-APC-A750 (clone LS198-4-3) as Dura clone IM B cells. Anti-CD31-
Pacific blue (clone 5.6E), anti-CD62L-APC750 (clone DREG56), anti-CD3-
FITC (clone UCHT-1), CD4-PE (clone 13B8.2) and CD45-PC5.5 (clone J33).
Anti-CD45-Krome Orange (clone J33), anti-CD3-APC-A750 (clone UCHT-1),
antiCD4-APC (clone 13B8.2), antiCD8-A700 (clone B9.11), anti-CD45RA-
FITC (clone 2H4), CCR7-PE (clone G043H7), anti-PD-1-PC5.5 (clone
PD13.5), anti-CD57-PB (NC1) as Dura clone IM T-cell subsets from Beckman
Coulter. Hundred microlitres of blood was added to the desired cocktail of
antibodies and incubated for 20 min at room temperature. Hundred microlitres
of lysing solution optilyse-B or VersaLyse was added according to the
manufacture recommendation. This was followed up with a wash step and
then acquisition of the sample using Navios flow cytometer (Brea, CA, USA).
Whole-exome capture sequencing
The Illumina paired-end genomic DNA sample preparation kit (PE-102-1001,
Illumina, San Diego, CA, USA) was used for preparing the libraries including
end repair, A-tailing and ligation of the Illumina adaptors. Each sample was
prepared with an index using the Illumina multiplexing sample preparation
oligonucleotide kit (PE-400-1001, Illumina) and then pooled in batches of six
in equimolar amounts prior to exome enrichment. The Illumina TruSeq exome
kit (FC-121-1008, Illumina) was used to capture the human exome for each
sample pool. Each 6-plex exome enriched library was sequenced in two lanes of
an Illumina HiSeq 2000 with version 2 chemistry as 100 bp paired-end reads.
Sequence reads were mapped to the GRCh37 assembly of the reference
human genome using the default parameters of the Burrows–Wheeler Aligner
(bio-bwa.sourceforge.net).14 Untrimmed reads were aligned allowing a
maximum of two sequence mismatches and reads with multiple mappings to
the reference genome were discarded along with PCR duplicates. Sequence
variants were identified with SAMtools (samtools.sourceforge.net)15 and
annotated using Annovar (http://annovar.openbioinformatics.org).16
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